Expressive

rs12190392 - RPL21P61 - LNC-LBCS

Magnitude 2.2 · 1 study on file

Reported associations

  • A year of COVID-19 GWAS results from the GRASP portal reveals potential genetic risk factors - Unknown journal (n.d.) · Unknown authors · PubMed 35224516

    ABSTRACT: Host genetic variants influence the susceptibility and severity of several infectious diseases, and the discovery of genetic associations with coronavirus disease 2019 (COVID-19) phenotypes could help to develop new therapeutic strategies to decrease its burden. Between May 2020 and June 2021, we used COVID-19 data released periodically by UK Biobank and performed 65 genome-wide association studies in up to 18 releases of COVID-19 susceptibility (n = 18,481 cases in June 2021), hospitalization (n = 3,260), severe outcomes (n = 1,244), and deaths (n = 1,104), stratified by sex and ancestry. In coherence with previous studies, we observed two independent signals at the chr3p21.31 locus (rs73062389-A, odds ratio [OR], 1.21 (P = 4.26 × 10−15) and rs71325088-C, OR, 1.62 [P = 2.25

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Lifestyle

  • Enhanced COVID-19 prevention during high-transmission periods Moderate

    Elevated genetic risk of severe disease supports targeted behavioral prevention when community transmission is high.

    Apply masking and distancing during high community transmission; prioritize ventilation indoors; limit crowded indoor settings during surges.

Screening

  • COVID-19 severity risk and personalized prevention strategy Moderate

    Genetic variant rs12190392 risk allele A is associated with increased COVID-19 severity (OR 0.417-0.465) in large GWAS cohorts; personalized risk stratification supports preventive planning.

  • Rapid escalation to medical care if COVID-19 symptoms develop Moderate

    Carriers of rs12190392 risk allele show higher severity risk; early medical intervention and antiviral therapy are time-sensitive and potentially high-impact.

    Contact provider at first respiratory symptom; pursue testing and antiviral evaluation within 48 hours of symptom onset.